Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $21,480.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 716 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $21,480.00. Following the completion of the transaction, the chief operating officer now owns 343,311 shares in the company, valued at approximately $10,299,330. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Enliven Therapeutics Price Performance

ELVN stock opened at $28.98 on Friday. The business’s fifty day moving average price is $24.62 and its two-hundred day moving average price is $22.93. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -15.02 and a beta of 1.10. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. Research analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of ELVN. Quest Partners LLC increased its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. EntryPoint Capital LLC bought a new position in Enliven Therapeutics in the 1st quarter valued at approximately $167,000. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics during the third quarter worth $256,000. The Manufacturers Life Insurance Company acquired a new position in Enliven Therapeutics during the 2nd quarter worth about $322,000. Finally, Blackstone Inc. acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $443,000. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.